Barely a month after Novartis (NVS) won U.S. regulatory approval for its gene therapy — the most expensive in the world — nearly a dozen insurers are taking steps to restrict coverage, a trend that is concerning for gene therapies more broadly, according to a Wall Street analyst.

At issue is Zolgensma, a gene therapy product for infants with spinal muscular atrophy, or SMA, an inherited disease that causes progressive loss of muscle function. The most severe form of SMA causes infants to die or need permanent breathing support by the age of 2. The  “one-and-done” treatment is considered a miracle cure by some, but the $2.125 million price tag is controversial.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Just as pharma companies have espoused the mantra “we don’t want to leave money on the table,” should we be surprised to observe that the insurers are reticent “to put money on the table.” Two opposites, time will tell where they meet.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy